Atsushi Nagai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Atsushi Nagai has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Kazutetsu Aoshiba
Tokyo Medical University Ibaraki Medical Center Department of Respiratory Medicine Ibaraki, Japan
3 shared publications Hiroko Suzuki
1 shared publication- Hiroyuki Nakamura
Tokyo Medical University Ibaraki Medical Center Department of Respiratory Medicine Ibaraki, Japan
1 shared publication - Kazuhiro Yamaguchi
Department of Respiratory Medicine, Tokyo Medical University, Tokyo 160-0023, Japan
1 shared publication - Masayuki Itoh
Department of Respiratory Medicine Kashiwa Tanaka Hospital Chiba Japan
1 shared publication Naoko Yokohori
1 shared publication
Latest Publications
- 1 August 2014
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 112, 9-15
Promotion of adipogenesis by an EP2 receptor agonist via stimulation of angiogenesis in pulmonary emphysema
- 1 August 2014
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 112, 9-15
Promotion of adipogenesis by an EP2 receptor agonist via stimulation of angiogenesis in pulmonary emphysema
- 1 January 2007
- Vol. 45 (1) , 3-7
[Seventy-five cases in which serum concentrations of cotinine were monitored prior to nicotine replacement therapy for smoking cessation].
We investigated the relationships between serum concentrations of cotinine and tests for nicotine dependence, exhaled carbon monoxide concentration, the urine concentration score of nicotine/cotinine/3-hydroxycotinine, cigarettes per day and cigarette index, in cases seeking medical advice in our hospital from April 2004 to November 2005. There was a significantly positive correlation between serum concentrations of cotinine and nicotine dependence, exhaled carbon monoxide concentration and the urine concentration score of nicotine/ cotinine/3-hydroxycotinine. In particular, the greatest positive correlation is between serum concentrations of cotinine and exhaled carbon monoxide concentration. There is no significant correlation between serum concentrations of cotinine and cigarettes per day and the cigarette index. To check exhaled carbon monoxide concentration is a useful index in nicotine replacement therapy for smoking cessation.
- 1 January 2007
- Vol. 45 (1) , 3-7
[Seventy-five cases in which serum concentrations of cotinine were monitored prior to nicotine replacement therapy for smoking cessation].
We investigated the relationships between serum concentrations of cotinine and tests for nicotine dependence, exhaled carbon monoxide concentration, the urine concentration score of nicotine/cotinine/3-hydroxycotinine, cigarettes per day and cigarette index, in cases seeking medical advice in our hospital from April 2004 to November 2005. There was a significantly positive correlation between serum concentrations of cotinine and nicotine dependence, exhaled carbon monoxide concentration and the urine concentration score of nicotine/ cotinine/3-hydroxycotinine. In particular, the greatest positive correlation is between serum concentrations of cotinine and exhaled carbon monoxide concentration. There is no significant correlation between serum concentrations of cotinine and cigarettes per day and the cigarette index. To check exhaled carbon monoxide concentration is a useful index in nicotine replacement therapy for smoking cessation.
- 15 August 2003
- Vol. 63 (16) , 5054-9
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
The inappropriate regeneration of sequentially injured epithelium is an important process leading to pulmonary fibrosis. Previous studies have shown that the epithelial expression of epidermal growth factor receptor (EGFR) is increased in fibrotic lung tissue, compared with normal lung tissue, suggesting that EGFR-mediated signaling is involved in epithelial regeneration in fibrotic lung diseases. We examined the effect of EGFR inhibition using ZD1839, a selective EGFR tyrosine kinase inhibitor (TKI), on bleomycin-induced pulmonary fibrosis in mice. ICR mice were administered a single intratracheal injection of bleomycin (5 units/kg) on day 1. ZD1839 (200 mg/kg) or vehicle alone were administered p.o. 1 h before this injection and on days 1-5 each week for 3 weeks. Lung tissue was harvested on day 21. Lung histology and collagen analysis performed on day 21 showed more severe fibrosis in the mice receiving both bleomycin and the EGFR-TKI than in the mice receiving bleomycin and the vehicle. An immunohistochemistry analysis showed that phosphorylated EGFR and proliferation cell nuclear antigen were highly expressed by the regenerated epithelial cells in the mice treated with bleomycin and the vehicle. In contrast, the expression of these antigens was attenuated in the mice treated with bleomycin and the EGFR-TKI. In vitro studies also demonstrated that the addition of ZD1839 at a concentration of < or =1 microM suppressed the proliferation of type II-like epithelial cells (A549) but not that of lung fibroblasts (IMR90). These results suggest that the inhibition of EGFR phosphorylation augments bleomycin-induced pulmonary fibrosis by reducing regenerative epithelial proliferation. Our data suggest that EGFR-TKIs should be used with caution in cancer patients with pulmonary fibrosis.
- 15 August 2003
- Vol. 63 (16) , 5054-9
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
The inappropriate regeneration of sequentially injured epithelium is an important process leading to pulmonary fibrosis. Previous studies have shown that the epithelial expression of epidermal growth factor receptor (EGFR) is increased in fibrotic lung tissue, compared with normal lung tissue, suggesting that EGFR-mediated signaling is involved in epithelial regeneration in fibrotic lung diseases. We examined the effect of EGFR inhibition using ZD1839, a selective EGFR tyrosine kinase inhibitor (TKI), on bleomycin-induced pulmonary fibrosis in mice. ICR mice were administered a single intratracheal injection of bleomycin (5 units/kg) on day 1. ZD1839 (200 mg/kg) or vehicle alone were administered p.o. 1 h before this injection and on days 1-5 each week for 3 weeks. Lung tissue was harvested on day 21. Lung histology and collagen analysis performed on day 21 showed more severe fibrosis in the mice receiving both bleomycin and the EGFR-TKI than in the mice receiving bleomycin and the vehicle. An immunohistochemistry analysis showed that phosphorylated EGFR and proliferation cell nuclear antigen were highly expressed by the regenerated epithelial cells in the mice treated with bleomycin and the vehicle. In contrast, the expression of these antigens was attenuated in the mice treated with bleomycin and the EGFR-TKI. In vitro studies also demonstrated that the addition of ZD1839 at a concentration of < or =1 microM suppressed the proliferation of type II-like epithelial cells (A549) but not that of lung fibroblasts (IMR90). These results suggest that the inhibition of EGFR phosphorylation augments bleomycin-induced pulmonary fibrosis by reducing regenerative epithelial proliferation. Our data suggest that EGFR-TKIs should be used with caution in cancer patients with pulmonary fibrosis.